文献速递系统性红斑狼疮

皮下注射阿尼鲁单抗治疗系统性红斑狼疮的疗效与安全性:一项随机3期研究

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study.
PubMed 文献 · Arthritis Rheumatol · 2026-02-17

TULIP-SC是一项跨国3期双盲安慰剂对照试验,评估皮下注射阿尼鲁单抗120mg每周一次治疗中重度SLE的疗效与安全性。预设中期分析(220例)达到主要终点,BICLA应答率差异15.5%(95%CI 2.3-28.6,P=0.0211);全分析(367例)显示阿尼鲁单抗在维持低剂量糖皮质激素下BICLA应答率更高(56.2% vs 34.0%),安全性可接受。

要点

  • 皮下阿尼鲁单抗120mg每周一次显著提高52周BICLA应答率,中期分析差异15.5%。
  • 全分析中阿尼鲁单抗组56.2% vs 安慰剂34.0%达到BICLA应答且维持低/减量激素。
  • 严重不良事件发生率两组接近(11.9% vs 10.4%),带状疱疹发生率3.8% vs 1.1%。

核心结论

  • 皮下阿尼鲁单抗联合标准治疗在中重度SLE患者中显示出显著且有临床意义的疗效,安全性可接受,与静脉阿尼鲁单抗已知特征一致。

研究设计与样本

  • 跨国、3期、双盲、安慰剂对照TULIP-SC试验,成人中重度SLE患者按1:1随机接受皮下阿尼鲁单抗120mg或安慰剂每周一次共52周。
  • 预设中期分析仅正式检验主要终点(52周BICLA应答的治疗差异),关键次要终点及其他终点在全分析中检验。

主要发现

  • 中期分析(220例,阿尼鲁单抗109例,安慰剂111例)达到主要终点:BICLA应答率59.4% vs 43.9%,差异15.5%(95%CI 2.3-28.6,P=0.0211)。
  • 全分析(367例,阿尼鲁单抗184例,安慰剂183例)中,阿尼鲁单抗组更多患者达到BICLA应答且维持低/减量口服糖皮质激素至52周(56.2% vs 34.0%,差异22.3%,95%CI 12.3-32.2,P<0.0001)。
  • 首次持续BICLA应答时间缩短(HR 2.2,95%CI 1.5-3.2,P<0.0001)。
  • 52周DORIS缓解率和低狼疮疾病活动状态达成率治疗差异均利于阿尼鲁单抗(分别为14.2%,95%CI 5.6-22.8,P=0.0012;14.1%,95%CI 4.6-23.6,P=0.0038)。
  • 严重不良事件频率阿尼鲁单抗组11.9%、安慰剂组10.4%;带状疱疹频率分别为3.8%和1.1%。

关键数值与推荐

  • 主要终点为52周BICLA应答的治疗差异,中期分析中阿尼鲁单抗组59.4% vs 安慰剂组43.9%,差异15.5%(95%CI 2.3-28.6,P=0.0211)。
  • 全分析中BICLA应答且维持低/减量口服糖皮质激素至52周的比例阿尼鲁单抗组56.2% vs 安慰剂组34.0%,差异22.3%(95%CI 12.3-32.2,P<0.0001)。
  • 首次持续BICLA应答的HR为2.2(95%CI 1.5-3.2,P<0.0001)。
  • 52周DORIS缓解率治疗差异14.2%(95%CI 5.6-22.8,P=0.0012),低狼疮疾病活动状态达成率差异14.1%(95%CI 4.6-23.6,P=0.0038)。

临床怎么用

  • 对于接受标准治疗仍存在中重度疾病活动的SLE成人患者,皮下阿尼鲁单抗120mg每周一次可作为增加治疗选择,有助于提高BICLA应答并减少激素用量。
  • 治疗期间需关注带状疱疹发生风险(阿尼鲁单抗组3.8% vs 安慰剂组1.1%),严重不良事件频率与安慰剂接近。

局限性

  • 预设中期分析仅正式检验主要终点,关键次要终点在全分析中检验,可能影响部分终点统计效力。
  • 原文未报告长期安全性数据及与静脉剂型的直接对比。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The multinational, phase 3, double-blind, placebo-controlled TULIP-SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. METHODS: Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 randomization). Only the primary endpoint (treatment difference in BILAG-based Composite Lupus Assessment [BICLA] response at 52 weeks) was formally tested in a preplanned interim analysis; key secondary and other endpoints were tested in the full analysis. RESULTS: At the interim analysis (220 patients, anifrolumab: n = 109; placebo: n = 111), the primary endpoint was met (anifrolumab vs placebo: 59.4% vs 43.9%; BICLA response difference 15.5%, 95% confidence interval [95% CI] 2.3-28.6; P = 0.0211). The full analysis included 367 patients (anifrolumab: n = 184; placebo: n = 183). Versus placebo, more patients treated with anifrolumab attained a BICLA response while maintaining low/reduced oral glucocorticoid doses through week 52 (56.2% vs 34.0%; difference 22.3%, 95% CI 12.3-32.2; P < 0.0001), and the time to first sustained BICLA response was reduced (hazard ratio 2.2, 95% CI 1.5-3.2; P < 0.0001). Treatment differences in week 52 DORIS remission and Low Lupus Disease Activity State attainment rates favored anifrolumab over placebo (14.2%, 95% CI 5.6-22.8; P = 0.0012, and 14.1%, 95% CI 4.6-23.6; P = 0.0038). The frequencies of serious adverse events were 11.9% with anifrolumab and 10.4% with placebo; the frequencies of herpes zoster were 3.8% and 1.1%, respectively. CONCLUSION: Consistent with the well-established profile of intravenous anifrolumab, subcutaneous anifrolumab demonstrated significant, clinically meaningful treatment benefits when added to standard therapy, and an acceptable safety profile in patients with moderate to severe SLE.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Manzi S, Bruce IN, Morand EF, et al. Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study. Arthritis Rheumatol. 2026. PMID: 41466456. doi:10.1002/art.70041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。